for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG (ADR)

NVS

Latest Trade

83.15USD

Change

0.81(+0.98%)

Volume

1,587,923

Today's Range

82.99

 - 

83.35

52 Week Range

77.04

 - 

98.52

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
82.34
Open
83.16
Volume
1,587,923
3M AVG Volume
41.44
Today's High
83.35
Today's Low
82.99
52 Week High
98.52
52 Week Low
77.04
Shares Out (MIL)
2,236.74
Market Cap (MIL)
205,713.20
Forward P/E
13.28
Dividend (Yield %)
3.84

Next Event

Q3 2021 Novartis AG Earnings Release

Latest Developments

More

Novartis Says FDA And EMA Filing Acceptances Of Beovu For Patients With Diabetic Macular Edema

Novartis Unit Sandoz Completes Acquisition Of GSK's Cephalosporin Business

Novartis To Present Data On Kesimpta, Mayzent

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG (ADR)

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

4056

Switzerland

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Lead Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

Steven Baert

Chief People & Organization Officer, Member of the Executive Committee

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

51.9K

2019

47.4K

2020

48.7K

2021(E)

51.9K
EPS (USD)

2018

5.150

2019

5.400

2020

5.780

2021(E)

6.276
Price To Earnings (TTM)
21.06
Price To Sales (TTM)
3.99
Price To Book (MRQ)
3.45
Price To Cash Flow (TTM)
13.65
Total Debt To Equity (MRQ)
66.19
LT Debt To Equity (MRQ)
49.02
Return on Investment (TTM)
9.53
Return on Equity (TTM)
7.25

Latest News

Latest News

Novartis buys gene therapy firm Arctos Medical in vision loss treatment push

Swiss drugmaker Novartis said on Tuesday it has bought gene therapy specialist Arctos Medical for an undisclosed amount, aiming to boost its efforts to find treatments for severe vision loss.

Novartis halts study of iscalimab in kidney transplant patients

Novartis has halted a clinical trial of CFZ533 (iscalimab) in kidney transplant patients after interim data showed it was not as good as tacrolimus-based treatment in preventing organ rejection, the Swiss group said on Friday.

Novartis signs deal with Britain's NHS for new cholesterol drug Leqvio

Novartis AG said on Wednesday it had agreed a deal with Britain's healthcare service provider for use of the drugmaker's new anti-cholesterol drug Leqvio, after the country's healthcare cost agency NICE approved the medicine.

Novartis's Kymriah does not meet primary endpoint in late-stage study

Novartis said its Kymriah CAR-T therapy did not meet its primary endpoint of event-free survival in a phase III study in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment.

Novartis's Kymriah does not meet primary endpoint in phase III study

Novartis ag said its Kymriah to treat aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment did not meet its primary endpoint of event-free survival in a phase III study.

Novartis to launch new Zolgensma trial after FDA lifts restriction

Novartis will launch a new phase three study to expand the use of Zolgensma - the world's most expensive one time therapy at $2.1 million per patient treatment - after the U.S. regulator lifted its restrictions.

Novartis profit tops expectations as pandemic impact ebbs

Swiss drugmaker Novartis beat second-quarter sales and profit expectations on Wednesday, while keeping its 2021 guidance unchanged, as disruption from the coronavirus pandemic waned.

Novartis set to deliver 50 million CureVac COVID-19 vaccines this year

Novartis is still helping CureVac make COVID-19 vaccines and could expand its capacity to assist other vaccine manufacturers as well, finance chief Harry Kirsch told reporters on Wednesday.

Novartis posts Q2 profit beat as sales pick up

Novartis boosted its second-quarter core net income by a fifth, beating market expectations, the Swiss drugmaker reported on Wednesday, as it kept its 2021 guidance.

Novartis to make Leqvio for U.S. in Austria to overcome FDA delay

Novartis will manufacture anti-cholesterol drug Leqvio at its own plant in Austria to supply the United States as it seeks U.S. approval that has been delayed by regulatory concerns over a contractor's Italian facility.

Novartis weighs entry into mRNA technology -chairman tells paper

Swiss drugmaker Novartis could get into the hot field of messenger ribonucleic acid (mRNA) technology, which has come to the fore during the coronavirus pandemic, Chairman Joerg Reinhardt said in a newspaper interview.

Novartis contends Roche 'unjustly enriched' itself with $210 million in fees -lawsuit

Novartis AG wants Roche Holding AG to return $210 million after accusing its Swiss rival of inappropriately pocketing fees from a 16-year-old patent licensing agreement, according to a lawsuit in U.S. District Court.

Novartis fights Roche in $210 mln U.S. dispute over licensing fees

Novartis wants Roche to return $210 million after accusing its Swiss rival of inappropriately pocketing fees from a 16-year-old patent licensing agreement, according to a U.S. District Court lawsuit.

Novartis aims to bottle more than 50 million doses of BioNTech COVID-19 vaccine in 2021

Novartis aims to help manufacture more than 50 million doses of BioNTech's COVID-19 vaccine in 2021 at its Stein, Switzerland fill-and-finish facility, the Swiss drugmaker said, after the European Union's drug regulator approved the bottling plant.

Novartis prostate cancer drug receives U.S. FDA breakthrough designation

Swiss drugmaker Novartis AG has received breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental treatment for advanced castration-resistant prostate cancer, the company said on Wednesday.

Novartis to close Swiss plant, 50 jobs to go

Novartis plans to close a plant in the southern Swiss town of Locarno, the drugmaker said on Wednesday, citing falling demand for testing products.

Novartis' nuclear therapy helps men with prostate cancer live longer - data

Men with a deadly form of advanced prostate cancer who failed other treatments survived four months longer after getting an experimental, tumour-targeting radiation therapy from Swiss drugmaker Novartis, data released on Thursday showed.

Novartis signs deal that could lead to acquisition of Zurich start-up Cellerys

Novartis has signed a collaboration agreement and option to acquire Cellerys, a Zurich-based startup conducting research on a therapy to fight multiple sclerosis (MS), the Swiss drugmaker said on Tuesday.

UPDATE 1-Novartis, Molecular Partners to start clinical trials of COVID-19 drug

Swiss drugmakers Novartis and Molecular Partners said on Thursday they will start clinical trials for an investigational medicine they are developing to treat COVID-19, with the aim of being able to seek approval next year.

U.S. Supreme Court snubs Novartis appeal over arthritis drug Enbrel

The U.S. Supreme Court on Monday dashed Novartis AG's hopes of launching a generic version of Amgen Inc's multibillion-dollar rheumatoid arthritis Enbrel, declining to hear the company's challenge to two patents on the drug.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up